Biohaven Future Growth
Future criteria checks 2/6
Biohaven is forecast to grow earnings and revenue by 16.1% and 69.5% per annum respectively. EPS is expected to grow by 24.1% per annum. Return on equity is forecast to be -102.8% in 3 years.
Key information
16.1%
Earnings growth rate
24.1%
EPS growth rate
| Biotechs earnings growth | 30.2% |
| Revenue growth rate | 69.5% |
| Future return on equity | -102.8% |
| Analyst coverage | Good |
| Last updated | 13 Aug 2024 |
Recent future growth updates
Recent updates
Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
Jul 26Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
May 18We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate
Apr 06
Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)
Mar 01Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)
Feb 28Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)
Dec 08Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation
Dec 04Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True
Sep 27Biohaven's Valuation Challenge: Weighing Potential Against Setbacks
Aug 28Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation
Jul 22Biohaven: A Promising Investment In Innovative Neurological Therapies
Jun 14Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache
Jun 06Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?
Apr 06Biohaven's spinal muscular atrophy therapy gets FDA fast track status
Feb 21Biohaven Ltd: Assessing The Spinoff
Dec 07Biohaven Non-GAAP EPS of -$1.25
Nov 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 115 | -635 | -650 | -456 | 9 |
| 12/31/2025 | 11 | -659 | -621 | -444 | 9 |
| 12/31/2024 | 10 | -794 | -600 | -338 | 10 |
| 6/30/2024 | N/A | -747 | -485 | -480 | N/A |
| 3/31/2024 | N/A | -517 | -359 | -357 | N/A |
| 12/31/2023 | N/A | -408 | -335 | -332 | N/A |
| 9/30/2023 | N/A | -465 | -295 | -292 | N/A |
| 6/30/2023 | N/A | -431 | -299 | -293 | N/A |
| 3/31/2023 | N/A | -544 | -323 | -316 | N/A |
| 12/31/2022 | N/A | -570 | -304 | -298 | N/A |
| 9/30/2022 | N/A | -421 | -261 | -255 | N/A |
| 6/30/2022 | N/A | -407 | -205 | -204 | N/A |
| 3/31/2022 | N/A | -257 | -171 | -170 | N/A |
| 12/31/2021 | N/A | -214 | -147 | -146 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BHVN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BHVN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BHVN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BHVN's revenue (69.5% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: BHVN's revenue (69.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BHVN is forecast to be unprofitable in 3 years.